Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

Teerlink J. R., Diaz R., Felker G. M., Mcmurray J. J. V., Metra M., Solomon S. D., ...Daha Fazla

NEW ENGLAND JOURNAL OF MEDICINE, cilt.384, sa.2, ss.105-116, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 384 Sayı: 2
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1056/nejmoa2025797
  • Dergi Adı: NEW ENGLAND JOURNAL OF MEDICINE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, Abstracts in Social Gerontology, AgeLine, BIOSIS, CAB Abstracts, Chemical Abstracts Core, CINAHL, Educational research abstracts (ERA), EMBASE, Food Science & Technology Abstracts, Gender Studies Database, International Pharmaceutical Abstracts, MEDLINE, MLA - Modern Language Association Database, Public Affairs Index, Veterinary Science Database
  • Sayfa Sayıları: ss.105-116
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Among patients with heart failure and a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidence of a composite of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo.